Avalo Therapeutics (AVTX) Stock Price, News & Analysis

Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $8.51 to $9.88
• 50-Day Range: $4.10 to $9.36
• 52-Week Range: $3.39 to $16.00
• Volume: 148,096 shs
• Average Volume: 108,234 shs
• Market Capitalization: $123.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Avalo Therapeutics Stock Analysis - MarketRank™

Avalo Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 914th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Avalo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Avalo Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avalo Therapeutics are expected to grow in the coming year, from ($19.07) to ($4.70) per share.

Price to Book Value per Share Ratio

Avalo Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.91% of the float of Avalo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avalo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalo Therapeutics has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalo Therapeutics does not currently pay a dividend.

Dividend Growth

Avalo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.91% of the float of Avalo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avalo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalo Therapeutics has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.06

News Sentiment

Avalo Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for AVTX on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.25% of the stock of Avalo Therapeutics is held by insiders.

Percentage Held by Institutions

87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVTX Stock Analysis - Frequently Asked Questions

How have AVTX shares performed this year?

Avalo Therapeutics' stock was trading at $7.43 at the start of the year. Since then, AVTX shares have increased by 26.0% and is now trading at $9.36.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by $0.49.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split on Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Who are Avalo Therapeutics' major shareholders?

Top institutional shareholders of Avalo Therapeutics include RWA Wealth Partners LLC (2.41%) and Geode Capital Management LLC (1.02%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, June Sherie Almenoff and Christopher Ryan Sullivan.
View institutional ownership trends.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avalo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTX
• CIK: 1534120
• Web: www.avalotx.com
• Phone: (410) 522-8707
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Avalo Therapeutics: $30.00
• High Price Target: $48.00
• Low Price Target: $15.00
• Potential Upside/Downside: +213.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.13 million
• Net Margins: N/A
• Pretax Margin: -10,451.70%
• Return on Equity: -48.48%
• Return on Assets: -35.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.44
• Quick Ratio: 12.44

Sales & Book Value

• Annual Sales: $440 thousand
• Price / Sales: 285.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.80 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 13,150,000
• Free Float: 13,119,000
• Market Cap: $125.71 million
• Optionable: Not Optionable
• Beta: 0.80